After 6 weeks of treatment, mice treated with gemcitabine, either as a single agent or in dual combination with HGF or c-MET inhibition, exhibited smaller tumours than IgG-treated controls, but statistically significant differences were only observed in G + Ci and the triple therapy (Hi + Ci + G) groups. The gene discussed is HGF; the disease is neoplasm.